Clinical trial
A Greek Observational Study on Relapse Rate and Sustained Virological Response in Naive CHC Patients, Treated With Pegylated Interferon Alpha-2b and Ribavirin in Daily Clinical Practice
NCT00724464 is registered in ClinicalTrials.gov with Merck Sharp & Dohme LLC as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Greek Observational Study on Relapse Rate and Sustained Virological Response in Naive CHC Patients, Treated With Pegylated Interferon Alpha-2b and Ribavirin in Daily Clinical Practice
- Lead sponsor
- Merck Sharp & Dohme LLC
- Phase
- Observational
- Overall status
- Completed
- Start date
- December 31, 2007
- Completion date
- October 31, 2010
- Enrollment
- 332 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.